NCT06026189Recruiting
Safely Reduce Cystoscopic Evaluations for Hematuria Patients
Source: ClinicalTrials.gov · Last updated 6 Sept 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The SeARCH-trial assess the clinical impact of a molecular urine test as a 'urine-first' strategy in the diagnostic workup of patients presenting with microscopic hematuria.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1100 (estimated)
- First submitted
- 1 Aug 2023
- Start date
- 31 May 2023
- Primary completion date
- 31 May 2026
- Lead sponsor
- Erasmus Medical Center
- Diseases
- Bladder cancer, Childhood cancers
- NCT number
- NCT06026189
What you commit to
- Study type: Interventional
- Planned participants: 1100
- From 31 May 2023 to the primary completion date, 31 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of urothelial bladder- or urinary tract cancer
Other
- Presence of macroscopic (visible) hematuria
- Woman who is or may be pregnant
Who the study is looking for
- Microscopically confirmed microscopic hematuria of voided urine defined as ≥3 erythrocytes per high power field
- Male patients ≥40 years
- Female patients ≥50 years
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SeARCH-trial Pijpers Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.